Cidara Therapeutics, INC Form 4 insider transactions
Director Chrysa Mineo reports acquisition of stock options in Cidara Therapeutics.
Theodore R. Schroeder, a director of Cidara Therapeutics, acquired stock options exercisable for 2,125 shares of common stock on July 18, 2024.
Director Ryan Spencer reports acquisition of stock options in Cidara Therapeutics.
Director Laura Tadvalkar acquired stock options in Cidara Therapeutics, holding them for the benefit of RA Capital Healthcare Fund.
Cidara Therapeutics' CEO, Jeffrey Stein, recently purchased 8,000 shares of common stock at an average price of $13.21 per share.
RA Capital Management and related parties report the acquisition of stock options in Cidara Therapeutics, Inc. on April 26, 2024.
Director Ryan Spencer acquired 4,250 stock options in Cidara Therapeutics on April 26, 2024, at an exercise price of $12.63.
Director James Merson acquired stock options in Cidara Therapeutics, Inc. on April 26, 2024.
Director Laura Tadvalkar acquired 4,250 stock options in Cidara Therapeutics, but disclaims beneficial ownership due to an arrangement with RA Capital Management.
Shane Ward, COO & CLO of Cidara Therapeutics, reports acquiring 120,000 shares of common stock and 250,000 employee stock options on March 15, 2024.
Cidara Therapeutics' CFO, Preetam Shah, reports acquisition of common stock and stock options, signaling changes in beneficial ownership.
Leslie Tari, Chief Scientific Officer of Cidara Therapeutics, reports the acquisition of restricted stock units and stock options, along with a disposition of common stock.
Taylor Sandison, Chief Medical Officer of Cidara Therapeutics, reports the acquisition of restricted stock units and stock options.
Cidara Therapeutics' CEO, Jeffrey Stein, acquired 1,040,000 stock options on March 15, 2024, exercisable at $0.6849 per share.
Cidara Therapeutics CEO Jeffrey Stein disposed of shares to cover tax obligations arising from RSU vesting.
Leslie Tari, Chief Scientific Officer of Cidara Therapeutics, sold shares to cover tax withholding obligations related to the vesting and settlement of RSUs.
Taylor Sandison, Chief Medical Officer of Cidara Therapeutics, sold shares to cover tax withholding obligations related to the vesting and settlement of RSUs.
Shane Ward, COO & CLO of Cidara Therapeutics, sold shares to cover tax withholding obligations related to the vesting and settlement of RSUs.
Cidara Therapeutics CFO Preetam Shah sold 18,931 shares of common stock on March 11, 2024, to cover tax withholding obligations related to the vesting and settlement of RSUs.